Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this observational study, researchers found that new users of tirzepatide experienced a higher incidence of alopecia compared to semaglutide users over a 12-month period, with increased risk persisting even when accounting for achieved weight loss and treatment duration.

In this study, researchers found that both direct and witnessed trauma in mice were linked to lower levels of the neurosteroid allopregnanolone, and that boosting neurosteroidogenesis may alleviate PTSD-like symptoms, suggesting potential treatment strategies for PTSD stemming from either trauma type.

Clofazimine successfully treated a man's ashy dermatosis, clearing his skin lesions.

This study suggests that using vitamin A, vitamin E, and vitamin C for two months may enable a reduction in corticosteroid dosage for alopecia areata, potentially mitigating associated side effects.

In this study, the safety profiles of four treatments for early rheumatoid arthritis were assessed over one year, and the most serious side effects necessitating treatment discontinuation were noted in the leflunomide group, whereas no such withdrawals occurred in the methotrexate plus prednisolone group.

This study found that medroxyprogesterone acetate treatment in women with PCOS reduced hyperandrogenism-related hormonal levels and improved skin conditions without affecting lipid or carbohydrate metabolism.

This retrospective cohort study found that both spironolactone and bicalutamide significantly improved Sinclair grade in women with female pattern hair loss over 24 months, but spironolactone, especially at doses above 100 mg/day, resulted in greater efficacy, required less monitoring, and maintained comparable safety.

The document doesn't provide enough information to summarize.

This study found that combining a GnRH agonist with a low-dose oral contraceptive was more effective in treating hirsutism than either agent alone and prevented hypoestrogenic side effects.

This study found that metformin's effect on reducing prolactin levels is less pronounced in women with PCOS compared to control subjects, likely due to higher endogenous testosterone levels, despite improvements in insulin sensitivity in both groups after six months of treatment.